Market Overview

Rodman & Renshaw Upgrades NxStage Medical


Rodman & Renshaw upgraded its NxStage (NASDAQ: NXTM) rating to Market Perform in a research report published today.

In the report, Rodman & Renshaw states, "We are upgrading our rating to a Market Perform. The stock is close to our PT and given the risks we see on the horizon, is fairly valued at the current levels."

Shares of NxStage closed today at $19.27, up 13.62% from Tuesday's market close.

Posted-In: Rodman & RenshawAnalyst Color Upgrades Analyst Ratings


Related Articles (NXTM)

View Comments and Join the Discussion!

Partner Center